Clinical and Economic Consequences of Inhaled Corticosteroid Doses and Particle Size in Triple Inhalation Therapy for COPD: Real-Life Study

References

• VogelmeierCF, CrinerGJ, MartinezFJ, et al. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Lung Disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195:557–582. doi:10.1164/rccm.201701-0218PP28128970
   PubMed Web of Science ®Google Scholar
• KileyJP, GibbonsGH. COPD national action plan: addressing a public health need together. Chest. 2017;152:698–699. doi:10.1016/j.chest.2017.08.115528991541
   PubMed Web of Science ®Google Scholar
• BlancoI, DiegoI, BuenoP, et al. Geographical distribution of COPD prevalence in Europe, estimated by an inverse distance weighting interpolation technique. Int J Chron Obstruct Pulmon Dis. 2017;13:57–67. doi:10.2147/COPD.S15085329317811
   PubMed Web of Science ®Google Scholar
• AlfagemeI, de LucasP, AncocheaJ, et al. 10 years after EPISCAN: a new study on the prevalence of COPD in Spain -a summary of the EPISCAN II protocol. Arch Bronconeumol. 2019;55:38–47. doi:10.1016/j.arbres.2018.05.01130612602
   PubMed Web of Science ®Google Scholar
• Sicras-MainarA, Rejas-GutiérrezJ, Navarro-ArtiedaR, Ibáñez-NollaJ. The effect of quitting smoking on costs and healthcare utilization in patients with chronic obstructive pulmonary disease: a comparison of current smokers versus ex-smokers in routine clinical practice. Lung. 2014;192:505–518. doi:10.1007/s00408-014-9592-724816902
   PubMed Web of Science ®Google Scholar
• MiravitllesM, MurioC, GuerreroT, GisbertR; on behalf of the DAFNE study group. Costs of chronic bronchitis and COPD. A one year follow-up study. Chest. 2003;123:784–791. doi:10.1378/chest.123.3.78412628879
   PubMed Web of Science ®Google Scholar
• SicrasA, HuertaA, NavarroR, IbañezJ. Use of resources and associated costs of chronic obstructive pulmonary disease exacerbations: A population based retrospective study. Semergen. 2014;40:189–197. doi:10.1016/j.semerg.2013.10.00224485969
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). From the global strategy for the diagnosis, management and prevention of COPD; 2019 Available from: http://goldcopd.org. Accessed 818, 2019.
   Google Scholar
• MiravitllesM, Soler-CataluñaJJ, CalleM, et al. Spanish guidelines for management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53:324–335. doi:10.1016/j.arbres.2017.03.01828477954
   PubMed Web of Science ®Google Scholar
• SinghD, PapiA, CorradiM, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388:963–973. doi:10.1016/S0140-6736(16)31354-X27598678
   PubMed Web of Science ®Google Scholar
• LipsonDA, BarnacleH, BirkR, et al. FULFIL trial: once-daily triple therapy in patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017;196:438–446. doi:10.1164/rccm.201703-0449OC28375647
   PubMed Web of Science ®Google Scholar
• Alcázar NavarreteB, CasanovaC, MiravitllesM, de LucasP, RiescoJA, Rodríguez González-MoroJM; Working Group. “Consensus document on the appropriate use of inhaled corticosteroids in COPD”. Correct use of inhaled corticosteroids in chronic obstructive pulmonary disease”: a consensus document. Arch Bronconeumol. 2015;51:193–198. doi:10.1016/j.arbres.2014.11.00125540900
   PubMed Web of Science ®Google Scholar
• MagnussenH, DisseB, Rodriguez-RoisinR, et al. WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285–1294. doi:10.1056/NEJMoa140715425196117
   PubMed Web of Science ®Google Scholar
• WatzH, TetzlaffK, WoutersEF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4:390–398. doi:10.1016/S2213-2600(16)00100-427066739
   PubMed Web of Science ®Google Scholar
• LipworthB, ManoharanA, AndersonW. Unlocking the quiet zone: the small airway asthma phenotype. Lancet Respir Med. 2014;2:497. doi:10.1016/S2213-2600(14)70103-124899370
   PubMed Web of Science ®Google Scholar
• DhandR, CavanaughT, SkolnikN. COPD in primary care: key considerations for optimized management: considerations for optimal inhaler device selection in Chronic Obstructive Pulmonary Disease. J Fam Pract. 2018;67(2 Suppl):S19–S27.
   PubMed Web of Science ®Google Scholar
• SinghD, CorradiM, SpinolaM, et al. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. Int J Chron Obstruct Pulmon Dis. 2017;12:2917–2928. doi:10.2147/COPD.S14682229062229
   PubMed Web of Science ®Google Scholar
• BassamM, MayankV. Glucocorticoids - new recognition of our familiar friend. Chapter 23. Steroids in asthma: friend or foe; 2012 Available from: https://www.intechopen.com/books/glucocorticoids-new-recognition-of-our-familiar-friend/steroids-in-asthma-friend-or-foe. Accessed 910, 2019.
   Google Scholar
• CharlsonME, PompeiP, AlesKL, MackenzieCR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383. doi:10.1016/0021-9681(87)90171-83558716
   PubMedGoogle Scholar
• World Health Organization. The anatomical therapeutic chemical classification system with defined daily doses (ATC/DDD): disponible en; 2020 http://www.who.int/classifications/atcddd/en/. Consultado: enero.
   Google Scholar
• VanfleterenL, FabbriLM, PapiA, PetruzzelliS, CelliB. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. Int J Chron Obstruct Pulmon Dis. 2018;13:3971–3981. doi:10.2147/COPD.S18597530587953
   PubMed Web of Science ®Google Scholar
• CazzolaM, CalzettaL, RoglianiP, MateraMG. Triple therapy versus dual bronchodilation and inhaled corticosteroids/long-acting β-agonists in COPD: accumulating evidence from network meta-analyses. Pulm Ther. 2019;5:117–126. doi:10.1007/s41030-019-00102-832026413
   PubMedGoogle Scholar
• IzquierdoJL, CosioBG. The dose of inhaled corticosteroids in patients with COPD: when less is better. Int J Chron Obstruct Pulmon Dis. 2018;13:3539–3547. doi:10.2147/COPD.S17504730498343
   PubMed Web of Science ®Google Scholar
• ChengSL, SuKC, WangHC, PerngDW, YangPC. Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia. Drug Des Devel Ther. 2014;8:601–607. doi:10.2147/DDDT.S63100
   PubMed Web of Science ®Google Scholar
• MorrosR, VediaC, Giner-SorianoM, CasellasA, AmadoE, BaenaJM; en representación de los investigadores del proyecto PNEUMOCORT. Community-acquired pneumonia in patients with chronic obstructive pulmonary disease treated with inhaled corticosteroids or other bronchodilators. Study PNEUMOCORT. Aten Primaria. 2019;51:333–340. doi:10.1016/j.aprim.2018.02.00729661670
   PubMed Web of Science ®Google Scholar
• VestboJ, PapiA, CorradiM, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919–1929. doi:10.1016/S0140-6736(17)30188-528385353
   PubMed Web of Science ®Google Scholar
• WedzichaJA, SinghD, VestboJ, et al. FORWARD Investigators. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014;108:1153–1162. doi:10.1016/j.rmed.2014.05.01324953015
   PubMed Web of Science ®Google Scholar
• PapiA, VestboJ, FabbriL, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X29429593
   PubMed Web of Science ®Google Scholar
• ScichiloneN, BenfanteA, MorandiL, BelliniF, PapiA. Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD. Patient Relat Outcome Meas. 2014;5:153–162.25473323
   PubMedGoogle Scholar
• PressVG, KonetzkaRT, WhiteSR. Insights about the economic impact of chronic obstructive pulmonary disease readmissions post implementation of the hospital readmission reduction program. Curr Opin Pulm Med. 2018;24:138–146. doi:10.1097/MCP.000000000000045429210750
   PubMed Web of Science ®Google Scholar
• Ehteshami-AfsharS, FitzGeraldJM, Doyle-WatersMM, SadatsafaviM. The global economic burden of asthma and chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2016;20(1):11–23. doi:10.5588/ijtld.15.047226688525
   PubMed Web of Science ®Google Scholar
• Sicras MainarA, HuertaA, Navarro ArtiedaR, MonsóE, LandisSH, IsmailaAS. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019;14:2121–2129. doi:10.2147/COPD.S21185431571848
   PubMed Web of Science ®Google Scholar
• IheanachoI, ZhangS, KingD, RizzoM, IsmailaAS. Economic burden of Chronic Obstructive Pulmonary Disease (COPD): a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:439–460. doi:10.2147/COPD.S23494232161455
   PubMed Web of Science ®Google Scholar
• TrudoF, KallenbachL, VaseyJ, et al. Clinical and economic burden of eosinophilic COPD in a large retrospective US cohort. Int J Chron Obstruct Pulmon Dis. 2019;14:2625–2637. doi:10.2147/COPD.S22000932063703
   PubMed Web of Science ®Google Scholar
• IzquierdoJL, MorenaD, GonzálezY, et al. Clinical management of COPD in a real-world setting. A big data analysis. Arch Bronconeumol. 2020:S0300-2896(20)30012–0. doi:10.1016/j.arbres.2019.12.025.
   Web of Science ®Google Scholar